PMID

Data

Article Title

Organization

A novel molecule with notable activity against multi-drug resistant tuberculosis.

University of Georgia

Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

University of Minnesota

Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.

Chinese Academy of Sciences

Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms.

Toyama Chemical

Glucuronidation of the red clover isoflavone irilone by liver microsomes from different species and human UDP-glucuronosyltransferases.

Max Rubner-Institute

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Glaxosmithkline

UDP-glucuronosyltransferases and clinical drug-drug interactions.

The University of British Columbia

Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis.

Biocon-Bristol Myers Squibb Research and Development Center

Improving Drug Delivery While Tailoring Prodrug Activation to Modulate

Biocon-Bristol Myers Squibb Research and Development Centre

The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.

Bristol Myers Squibb Research and Early Development

Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous

Agios Pharmaceuticals

Brain Penetrable Inhibitors of Ceramide Galactosyltransferase for the Treatment of Lysosomal Storage Disorders.

Sanofi R&D

Identification and Preclinical Evaluation of the Bicyclic Pyrimidine ?-Secretase Modulator BMS-932481.

Bristol-Myers Squibb

Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11?-Hydroxysteroid Dehydrogenase Type 1 (11?-HSD1).

Sk Chemicals

p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators.

China Pharmaceutical University

Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir.

TBA

Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.

Gwangju Institute of Science and Technology

Identification of second-generation P2X3 antagonists for treatment of pain.

Merck